News | November 14, 2013

Two Studies Demonstrate Efficacy for Prostate Cancer Treated With CyberKnife System

UCLA researchers evaluate long-term outcomes of more than 1,000 patients from multiple institutions

clinical trial study radiation therapy prostate technology accuray cyberknife
November 14, 2013 — Accuray Inc. announced the publication of two papers stemming from a large multi-center study of CyberKnife stereotactic body radiotherapy (SBRT) led by investigators at the University of California, Los Angeles (UCLA). 
 
The first paper, published in the September 2013 online issue of Radiotherapy & Oncology (commonly referred to as the Green Journal), found, in more than 1,000 patients with organ-confined prostate cancer, relapse-free survival rates were comparable to other established treatments at both three- and five-year intervals post-treatment. The second paper published in the October 10 issue of the International Journal of Radiation Oncology (commonly referred to as the Red Journal) demonstrated that CyberKnife SBRT (stereotactic body radiation therapy) was a well-tolerated treatment that allowed patients to return to their pre-treatment health-related quality of life (QoL).
 
“These studies confirm with a much larger patient population and longer follow-up what many smaller studies have already suggested: SBRT is an effective method for treating prostate cancer,” said Christopher King, Ph.D., M.D., professor of radiation oncology and urology, UCLA School of Medicine and lead author of the study. “Compact dose delivery and real-time tracking of prostate motion gave the authors of these studies the confidence to explore the potential of high-dose, extreme hypofractionation. Clinical outcomes so far validate the effectiveness and safety of treating patients with prostate cancer with minimal disruption to their lives.”
 
In the first paper from the study published in the Green Journal, titled, “Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials,” 1,100 patients with low-, intermediate- or high-risk prostate cancer were treated with the CyberKnife System and followed for a median of 36 months. Relapse-free survival rates were comparable to or better than other established treatments at both three- and five-year intervals post-treatment. Additionally, for the 135 patients with at least five years follow-up, disease-free survival was 99 percent for low-risk and 93 percent for intermediate-risk patients. 
 
In the second paper, “Health related quality of life after stereotactic body radiotherapy for localized prostate cancer,” published in the Red Journal, health-related QoL was assessed in 864 patients after prostate SBRT on the CyberKnife System. Reductions in urinary and bowel QoL recovered to baseline levels or better within six months and remained so over the long term. Sexual QoL declined in the first nine months in a manner that was no worse than that seen with other modern approaches to radiation therapy and observed in other studies. Overall, the QoL outcomes compared favorably to surgery and other kinds of radiotherapy.
 
The CyberKnife is equipped with the InTempo Adaptive Imaging System, which enables real-time tracking and correcting of the prostate during treatment. This image-guidance technology ensures the CyberKnife is on target, sparing normal tissue despite unpredictable, sometimes extensive prostate movement.
 

Related Content

Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

News | Radiation Therapy | April 22, 2019
April 22, 2019 — A new study finds wide state
Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
Deep Lens Closes Series A Financing for Digital AI Pathology Platform
News | Digital Pathology | April 09, 2019
Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further...
Uterine Fibroid Embolization Safer and as Effective as Surgical Treatment
News | Interventional Radiology | April 05, 2019
Uterine fibroid embolization (UFE) effectively treats uterine fibroids with fewer post-procedure complications compared...